La tobramycine dans la prise en charge de la mucoviscidose : Nouvelles opportunités thérapeutiques

Details

Supervisors

sans promoteur

Faculty

Faculté de pharmacie et des sciences biomédicales

Degree label

Master [120] en sciences pharmaceutiques, à finalité spécialisée

Abstract

enCystic fibrosis is the most common fatal genetic disorder in the Caucasian population. The primary cause of morbidity and mortality is the respiratory damage resulting mainly from chronic Pseudomonas aeruginosa infections. The first drug of choice is inhaled tobramycin. However, the efficacy of this antibiotic decreases sharply when Pseudomonas aeruginosa develop resistance mechanism, which consists of, among other things, the formation of a biofilm. Therefore, we have analyzed and compared recent trials in vitro, in vivo, and clinical, aimed at overcoming this resistance. They studied the administration of tobramycin in nanoparticle vectors with/without several anti-biofilm agents including a biofilm dispersing agent, a QS inhibiting agent or a chelating agent. The promising results of these studies present new therapeutic options that require further trials, including randomized, double-blind, large-scale clinical trials, to consider the validation of new treatments.